MCM
AXSM icon

Manchester Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Manchester Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12
Closed -$1K – 1030
2021
Q2 		$1K Buy
+12
New +$720 ﹤0.01% 732

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Manchester Capital Management's AXSM Position: Q3 2021 in Review

Manchester Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2021, closing a stake of 12 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in AXSM in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 171 funds tracked by Wall St. Rank hold AXSM as of Q3 2021.

  • Manchester Capital Management reported no remaining Axsome Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Manchester Capital Management sold 12 Axsome Therapeutics shares in Q3 2021, an estimated $1K.
  • Manchester Capital Management first reported a position in Axsome Therapeutics in Q2 2021 and held it in 1 quarter.
  • Manchester Capital Management's Axsome Therapeutics position peaked at $1K in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2021.

Based on Manchester Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.